Eledon Pharmaceuticals, Inc.

NasdaqCM:ELDN Stok Raporu

Piyasa değeri: US$253.9m

Eledon Pharmaceuticals Gelecekteki Büyüme

Future kriter kontrolleri 0/6

Eledon Pharmaceuticals şirketinin kazançlarının yıllık 33% oranında düşmesi, yıllık gelirinin ise yıllık 87.2% oranında artması bekleniyor. EPS'nin yıllık 10.8% oranında düşüşmesi bekleniyor.

Anahtar bilgiler

-33.0%

Kazanç büyüme oranı

-10.8%

EPS büyüme oranı

Biotechs kazanç büyümesi28.3%
Gelir büyüme oranı87.2%
Gelecekteki özkaynak getirisin/a
Analist kapsamı

Low

Son güncelleme20 Nov 2024

Gelecekteki son büyüme güncellemeleri

Recent updates

Eledon: Changing Scope Of Immunosuppressive Drug Space With Tegoprubart

Oct 29

We Think Eledon Pharmaceuticals (NASDAQ:ELDN) Needs To Drive Business Growth Carefully

Mar 22
We Think Eledon Pharmaceuticals (NASDAQ:ELDN) Needs To Drive Business Growth Carefully

Is Eledon Pharmaceuticals (NASDAQ:ELDN) In A Good Position To Deliver On Growth Plans?

Dec 05
Is Eledon Pharmaceuticals (NASDAQ:ELDN) In A Good Position To Deliver On Growth Plans?

Is Eledon Pharmaceuticals (NASDAQ:ELDN) In A Good Position To Deliver On Growth Plans?

Aug 10
Is Eledon Pharmaceuticals (NASDAQ:ELDN) In A Good Position To Deliver On Growth Plans?

We Think Eledon Pharmaceuticals (NASDAQ:ELDN) Needs To Drive Business Growth Carefully

Apr 27
We Think Eledon Pharmaceuticals (NASDAQ:ELDN) Needs To Drive Business Growth Carefully

Here's Why We're Watching Eledon Pharmaceuticals' (NASDAQ:ELDN) Cash Burn Situation

Jan 05
Here's Why We're Watching Eledon Pharmaceuticals' (NASDAQ:ELDN) Cash Burn Situation

Eledon adds 10% as FDA clears clinical trial for kidney disease candidate

Sep 06

Is Eledon Pharmaceuticals (NASDAQ:ELDN) In A Good Position To Invest In Growth?

Aug 31
Is Eledon Pharmaceuticals (NASDAQ:ELDN) In A Good Position To Invest In Growth?

Eledon gets FDA nod to start trial of organ rejection preventing therapy

Aug 01

Eledon begins dosing in early-stage study of tegoprubart in kidney transplant patients

Jul 18

Eledon gives update on development strategy for AT-1501 in renal transplantation

Apr 26

Eledon Pharmaceuticals (NASDAQ:ELDN) Is In A Good Position To Deliver On Growth Plans

Apr 14
Eledon Pharmaceuticals (NASDAQ:ELDN) Is In A Good Position To Deliver On Growth Plans

What Type Of Shareholders Make Up Eledon Pharmaceuticals, Inc.'s (NASDAQ:ELDN) Share Registry?

Feb 21
What Type Of Shareholders Make Up Eledon Pharmaceuticals, Inc.'s (NASDAQ:ELDN) Share Registry?

Here's Why We're Not Too Worried About Novus Therapeutics' (NASDAQ:NVUS) Cash Burn Situation

Dec 30
Here's Why We're Not Too Worried About Novus Therapeutics' (NASDAQ:NVUS) Cash Burn Situation

Novus Therapeutics (NVUS) Investor Presentation - Slideshow

Dec 18

Novus Therapeutics EPS misses by $3.76

Nov 16

Enrollment underway in Novus Therapeutics' mid-stage AT-1501 trial in neuromuscular disease

Nov 02

Kazanç ve Gelir Büyüme Tahminleri

NasdaqCM:ELDN - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
TarihGelirKazançlarSerbest Nakit AkışıFaaliyetlerden NakitAvg. Analist Sayısı
12/31/2026N/A-79-106N/A2
12/31/2025N/A-81-84N/A4
12/31/2024N/A-20N/AN/A5
9/30/2024N/A-25-37-37N/A
6/30/2024N/A-89-38-38N/A
3/31/2024N/A-129-38-38N/A
12/31/2023N/A-117-40-40N/A
9/30/2023N/A-145-40-40N/A
6/30/2023N/A-145-32-32N/A
3/31/2023N/A-89-30-30N/A
12/31/2022N/A-88-28-28N/A
9/30/2022N/A-38-28-28N/A
6/30/2022N/A-38-31-31N/A
3/31/2022N/A-36-32-32N/A
12/31/2021N/A-35-29-29N/A
9/30/2021N/A-32-29-29N/A
6/30/2021N/A-28-23-23N/A
3/31/2021N/A-23-18-18N/A
12/31/2020N/A-23-15-15N/A
9/30/2020N/A-21-8-8N/A
6/30/2020N/A-18-10-10N/A
3/31/2020N/A-19-12-12N/A
12/31/2019N/A-16-14-14N/A
9/30/2019N/A-16-15-15N/A
6/30/2019N/A-17-15-15N/A
3/31/2019N/A-16-14-14N/A
12/31/2018N/A-14-12-12N/A
9/30/2018N/A-12-11-11N/A
6/30/2018N/A-11N/A-12N/A
3/31/2018N/A-13N/A-16N/A
12/31/2017N/A-11N/A-15N/A
9/30/2017N/A-9N/A-14N/A
6/30/2017N/A-6N/A-12N/A
3/31/2017N/A-1N/A-5N/A
12/31/2016N/A-1N/A-5N/A
9/30/2016N/A-1N/A-6N/A
12/31/2015N/A-1N/A-4N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: ELDN önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Kazançlar ve Piyasa: ELDN önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Yüksek Büyüme Kazançları: ELDN önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Gelir ve Pazar: ELDN gelecek yıl gelir elde edemeyeceği tahmin ediliyor.

Yüksek Büyüme Geliri: ELDN gelecek yıl gelir elde edemeyeceği tahmin ediliyor.


Hisse Başına Kazanç Büyüme Tahminleri


Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: ELDN 'un Özsermaye Getirisi'nin 3 yıl içinde yüksek olmasının öngörülüp öngörülmediğini belirlemek için yeterli veri yok


Büyüyen şirketleri keşfedin